Royal Bank of Canada upgraded 10x Genomics to "Hold." The broader analyst consensus for 10x Genomics remains "Hold." Analysts set an average price target of $40.57. The stock experienced significant volatility, trading near the upper end of its 12-month range.
The rating change follows 10x Genomics' recent second-quarter earnings report, where the company beat expectations. However, some investors consider a softer near-term outlook as the company transitions to its new Atera platform. Company insiders sold approximately $6.3 million worth of shares over the past quarter.